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Abstract
Background: The objective of this research is to quantify the association between direct medical
costs attributable to type 2 diabetes and level of glycemic control.
Methods: A longitudinal analysis using a large health plan administrative database was performed.
The index date was defined as the first date of diabetes diagnosis and individuals had to have at least
two HbA1c values post index date in order to be included in the analyses. A total of 10,780
individuals were included in the analyses. Individuals were stratified into groups of good (N =
6,069), fair (N = 3,586), and poor (N = 1,125) glycemic control based upon mean HbA1c values
across the study period. Differences between HbA1c groups were analyzed using a generalized
linear model (GLM), with differences between groups tested by utilizing z-statistics. The analyses
allowed a wide range of factors to affect costs.
Results: 42.1% of those treated only with oral agents, 66.1% of those treated with oral agents and
insulin, and 57.2% of those treated with insulin alone were found to have suboptimal control
(defined as fair or poor) throughout the study period (average duration of follow-up was 2.95
years). Results show that direct medical costs attributable to type 2 diabetes were 16% lower for
individuals with good glycemic control than for those with fair control ($1,505 vs. $1,801, p < 0.05),
and 20% lower for those with good glycemic control than for those with poor control ($1,505 vs.
$1,871, p < 0.05). Prescription drug costs were also significantly lower for individuals with good
glycemic control compared to those with fair ($377 vs. $465, p < 0.05) or poor control ($377 vs.
$423, p < 0.05).
Conclusion: Almost half (44%) of all patients diagnosed with type 2 diabetes are at sub-optimal
glycemic control. Evidence from this analysis indicates that the direct medical costs of treating type
2 diabetes are significantly higher for individuals who have fair or poor glycemic control than for
those who have good glycemic control. Patients under fair control account for a greater proportion
of the cost burden associated with antidiabetic prescription drugs.
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Introduction
The worldwide burden of diabetes is significant and grow-
ing so rapidly that it is classified as a global epidemic. The
World Health Organization (WHO) estimates that over
177 million individuals live with diabetes, and approxi-
mately 4 million deaths each year are related to complica-
tions from the disease.[1] While 30 million cases were
documented in 1985, 300 million are expected by the year
2025, [1] largely due to the prevalence of type 2 diabetes,
which accounts for 90% of all diabetic cases. [2] In the
United States, there were approximately 6.5 million cases
in 1987 and 12.1 million in 2002. [3,4] Forecasts predict
that this number will increase to approximately 14.5 mil-
lion by 2010 and to 17.4 million by 2020. [5] As the dia-
betes epidemic expands, associated healthcare costs and
demands also continue to increase. [3] For example, the
direct medical costs associated with diabetes in the United
States in 2002 were estimated to $92 billion. [5] Moreo-
ver, the indirect costs associated with lost productivity due
to disability and mortality are estimated at an additional
$40 billion, resulting in total estimated expenditures for
diabetes approaching $132 billion.
Contributing to these large expenditures are the costs
associated with diabetes-related complications. Compli-
cations associated with diabetes include cardiovascular
disease, neuropathy, retinopathy, and nephropathy. [6]
The direct medical costs associated with diabetes-related
complications totaled $24.6 billion in 2002. [5] These
complications substantially increase not only the eco-
nomic burden for healthcare systems, but also the
patient's risk for disability, death, [5] and diminished
quality of life. [7-9]
Hemoglobin A1c (HbA1c), a clinical measure of ambient
blood glucose concentrations over the previous 3 month
time period, is recognized as a surrogate measure for the
risk of these costly complications. Supporting the use of
HbA1c as a surrogate measure for complication risk are
studies of the U.K. Prospective Diabetes Study (UKPDS)
cohort. UKPDS, originally a multi-center clinical trial
examining interventions to lower blood glucose and
blood pressure among patients with type 2 diabetes, dem-
onstrated that improved glycemic control reduces the risk
of microvascular (retinopathy, nephropathy, and neurop-
athy) and macrovascular (myocardial infarction, stroke)
complications. [10] Accordingly, many countries have
established guidelines for the treatment of type 2 diabetes
that include specific target percentage levels for HbA1c. For
instance, the American Diabetes Association advocates an
HbA1c level of less than or equal to 7%. [11] In addition,
the National Center for Quality Assurance Health
Employer Data and Information Set (NCQA/HEDIS) has
established a threshold HbA1c value of >9.% to indicate
individuals at poor glycemic control when evaluating the
performance of managed care plans.[12] Outside of the
United States, the United Kingdom's National Institute for
Clinical Excellence recommends a target HbA1c  goal
between 6.5% and 7.5%. [13] In addition, the European
Diabetes Policy Group identified individuals with HbA1c
levels of less than or equal to 6.5% as low risk. [14].
As HbA1c or glycemic control is considered a surrogate
measure for costly diabetic complications, it is also of
interest to examine the relationship between HbA1c and
healthcare utilization and cost. Previous studies have
explored the relationship between HbA1c levels of patients
with type 2 diabetes and healthcare resource use. Whether
examining baseline HbA1c levels and costs over a 3 year
follow up, mean HbA1c levels over a 3 year period and
adjusted rates for hospital admissions, or the impact of
HbA1c change on expenditures, the research suggests that
successful glycemic control positively affects ensuing
healthcare utilization and cost. [15-17] To supplement
these findings, the purpose of the present study was to
measure the recent healthcare utilization and cost of indi-
viduals with type 2 diabetes at varying HbA1c levels which
correspond to current guidelines. We hypothesized that
when considering diabetes-attributable healthcare utiliza-
tion, lower glycemic control would be significantly associ-
ated with lower direct medical costs.
Methods
Data for this analysis came from the Health Core Man-
aged Care Database. This limited, Health Insurance Porta-
bility and Accountability Act (HIPAA) compliant database
contains approximately 2.1 million individuals with med-
ical, pharmacy, and eligibility data in the health plan lines
of business with complete capture of healthcare provider
encounters. Data for the present study were obtained from
the Southeastern health plan of the database and covered
the time period from October 1, 1998 to April 30, 2003.
We examined the costs associated with a diagnosis of type
2 diabetes by focusing the analysis on individuals with
continuous insurance coverage who were diagnosed with
type 2 diabetes. Individuals were identified as having type
2 diabetes if they received an oral glucose lowering medi-
cation, or both insulin and a diagnosis of type 2 diabetes
(ICD-9 of 250.00, 250.10, 250.20, 250.30, 250.40,
250.50, 250.60, 250.70, 250.80, 250.90 (e.g., 250.x0) or
250.02, 250.12, 250.22, 250.32, 250.42, 250.52, 250.62,
250.72, 250.82, 250.92 (e.g. 250.x2)), or at least two diag-
noses of type 2 diabetes (ICD-9 of 250.x0 or 250.x2)
between the period of October 1, 1998 and April 30, 2001
(e.g. the identification period). We identified an individ-
ual's index date as first date of diagnosis of type 2 diabetes
or receipt of an antidiabetic agent (a sulphonylurea,
amino acid derivative, biguanide, meglitinide, alpha-glu-
cose inhibitor, insulin sensitizing agent, or antidiabeticCost Effectiveness and Resource Allocation 2006, 4:1 http://www.resource-allocation.com/content/4/1/1
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combination) during the identification period and
required that individuals have continuous insurance cov-
erage, at a minimum, from twelve months prior to twenty-
four months post-index date. An individual's post-period
was allowed to be as long as forty-three months, provided
they had continuous insurance coverage during the time-
period of interest. We also required that each individual
have at least two HbA1c values in the post-period. We
included in the analyses the 10,780 individuals who fit
the above criteria. Individuals were stratified into groups
of good (N = 6,069), fair (N = 3,586), and poor (N =
1,125) glycemic control based upon HbA1c values of ≤ 7,
>7 and ≤ 9, or >9, respectively, where HbA1c control
groups were based upon the mean HbA1c level in the last
year of the post-period.
The analysis focused on differences in costs for individu-
als with different levels of glycemic control. Costs were
measured as the direct medical payments associated an
inpatient or outpatient claims with a corresponding diag-
nosis of type 2 diabetes as well as receipt of any outpatient
antidiabetic prescription medication. Such payments
include both payments by insurance companies as well as
payments by patients. All costs were converted into 2003
dollars using the medical care component of the con-
sumer price index (Source: bls.gov). Costs are presented
per member per year in order to account for the differ-
ences in follow-up periods.
Descriptive statistics included mean (± standard deviation
[SD]) and median values for continuous data and relative
frequencies for categorical data. Continuous variables
were compared with analysis-of-variance (ANOVA) with
Scheffe test for multiple-comparisons. This post-hoc test
was chosen because it is more stringent (i.e., less likely to
make an alpha error) as compared to other tests. Categor-
ical variables were compared based on Pearson chi-
squared tests. The length of follow-up was not uniform for
all patients.
To determine if costs for post-index events were different
between index diagnoses, multivariate generalized linear
model techniques were used. Model covariates included
demographic characteristics, patient severity, complica-
tions and comorbidities of clinical relevance, and HbA1c
values. Patient demographic characteristics consisted of
the individual's age, sex, and type of insurance coverage.
Patient severity was proxied by previous resource health-
care use (e.g. prior year costs) as well as a count of distinct
medications prescribed during the year prior to index
date. In addition, disease prevalence was proxied by an
indicator variable equal to one if the individual was diag-
Table 1: International classification of diseases and current procedural terminology codes for complications and comorbidities
Complication or Comorbidity International Classification of Diseases – 9 – Clinical 
Modification Codes
Nephropathy 39.27, 39.42, 39.43, 39.53, 39.93, 39.94, 39.95, 54.98, 55.4, 55.6, 250.4x, 
403.xx, 404.xx, 405.01, 405.11, 405.91, 584.xx, 585.xx, 586.xx, 588.xx, 
753.0x, 753.1x, 791.xx, V42, V45.1, V56
Neuropathy 250.6x
Retinopathy 250.5x
Foot Ulcer 707.1x
Amputation 84.1x
Myocardial Infarction 410.0x, 412.x
Stroke/Transient ischemic attack 430.xx – 438.xx
Coronary Artery Bypass Surgery 36.1x, 36.2x, 36.3x
Angioplasty 36.01, 36.02, 36.03, 36.05, 36.09
Complication or Comorbidity Current Procedural Terminology Codes
Nephropathy 36800, 36810, 36815, 50300, 50340, 50360, 50365, 50370, 50380, 
90920, 90921, 90924, 90925, 90935, 90937, 90945, 90947, 90989, 
90993, 90997, 90999
Neuropathy
Retinopathy
Foot Ulcer
Amputation 26910, 27590–27592, 27594, 27596, 27598, 27880–27882, 27884, 
27886, 27888, 27889, 28800, 28805, 28810, 28820, 28825
Myocardial Infarction
Stroke 35301, 35390
Coronary Artery Bypass Surgery 33510–33545, 33572
Angioplasty 92980–92984, 92995–92996
Receipt of any of the diagnostic or procedure codes listed above in the year prior to the index date was used to measure the presence of a 
complication or comorbidity.Cost Effectiveness and Resource Allocation 2006, 4:1 http://www.resource-allocation.com/content/4/1/1
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nosed with type 2 diabetes (ICD-9 of 250.x0 or 250.x2) in
the 12 months prior to the index period. Since an individ-
ual's index date was based upon first diagnosis of type 2
diabetes or receipt of an antidiabetic agent during the
identification period, it is possible to be diagnosed with
diabetes prior to the index date. Indicator variables were
also constructed for the diabetic complications of neph-
ropathy, retinopathy, foot ulcer, and amputation as well
as for the comorbid conditions of myocardial infarction,
stroke, coronary artery bypass surgery, and angioplasty.
Identification of such variables were dependent upon
receipt of a diagnosis or procdure in the one year prior to
the index date. The diagnostic and procedure codes used
to identify each of the above complications or comorbid-
ities are given in Table 1. Finally, indicator variables were
constructed for different rules of identifying individuals
with type 2 diabetes. Specifically, indicator variables were
set equal to one if an individual received a diagnosis of
type 2 diabetes only or if an individual received insulin
plus a diagnosis of type 2 diabetes.
In estimating the multivariate regressions, costs associated
with post-index episodes were assumed to follow a
gamma-distribution. In addition, costs of care were
empirically determined to be linear on the natural loga-
rithm scale. Patient demographic characteristics, indica-
tors of patient severity, type 2 diabetes classification and
level of HbA1c control were included in the model, while
complications and comorbidites covariates with Wald p-
values of < 0.15 were considered significant and included
in the final model if they did not significantly change the
Bayesian Information Criteria scores. The final estimated
regression therefore included variables of clinical rele-
vance and best model fit. These models were used to pre-
dict estimated costs per member per year with covariates
held constant at their sample means. Statistical signifi-
cance was defined a priori at an alpha of less than 0.05. All
statistical analyses were performed using STATA version
8.2. [18]
Results
Table 2 illustrates differences in HbA1c levels across differ-
ent inclusion criteria for the study. Individuals who
received oral antidiabetes drugs only during the post-
period or were not receiving any antidiabetes medication
during the post-period were significantly more likely to
have HbA1c levels  ≤ 7%. In contrast, individuals who
received insulin only during the post-period or received
an oral antidiabetes drug and insulin during the post-
period were significantly more likely to have fair or poor
HbA1c values. Compared to individuals with fair control,
those in the poor control group were more likely to have
received both oral antidiabetes drugs and insulin during
the post-period and less likely have received only oral
antidiabetic medications or no medications during the
post-period.
Table 3 presents the characteristics of the 10,780 individ-
uals included in the analysis. Among the total population,
the average age was approximately 63 years, consisted of
more males than females (53% males), and was predom-
inantly Medicare insured (54%). The most common com-
plications or comorbidities were stroke (6.4%) and
neuropathy (4.6%). The majority of individuals (56%)
maintained good levels of HbA1c throughout the study
period (e.g., HbA1c ≤7%).
Table 3 also presents the characteristics of the individuals
based upon levels of HbA1c. Compared to individuals
with good glycemic control, individuals who achieved fair
(HbA1c values >7% and ≤9%) or poor (HbA1c values >9%)
glycemic control were significantly younger, were less
Table 2: Identification of individuals included in studyBy HbA1c levels
Inclusion Criteria Good HbA1c Fair HbA1c Poor HbA1c
Oral antidiabetic drugs only (no 
insulin)
4,265 (70%) 2,408 (67%)* 696 (62%)* ‡
Oral antidiabetic drugs plus insulin 424 (7%) 562 (16%)* 264 (23%)* ‡
Insulin only with ICD-9-CM code 
of Type 2 Diabetes
346 (6%) 350 (10%)* 112 (10%)*
No diabetic medication with at 
least two ICD-9-CM diagnoses of 
Type 2 Diabetes
1,034 (17%) 266 (7%)* 53 (5%)* ‡
Sample Size 6,069 3,586 1,125
Classification at any time during the post-period based upon inclusion/exclusion criteria for study.
In addition, individuals had to be continuously insured from at least 12 months prior and 24 months post index date and have at least 2 HbA1c values 
in the post-period.
Pairwise differences between groups tested using students t-test, z-statistic or Mann-Whitney test.
*Significant below 0.05 compared to the good control group
‡Significant below 0.05 between Fair and Poor control groupsCost Effectiveness and Resource Allocation 2006, 4:1 http://www.resource-allocation.com/content/4/1/1
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likely to be Medicare patients, were less likely to be newly
diagnosed with diabetes, and were less likely to suffer a
stroke. In addition, individuals with good HbA1c values
were significantly less likely to have been diagnosed with
diabetic complications neuropathy or retinopathy. Com-
pared to individuals with good glycemic control, individ-
uals with poor glycemic control had significantly lower
prior resource utilization, including total pharmacy med-
ication use, but were more likely to have been diagnosed
with retinopathy. There were no differences between the
three subgroups with regard to gender or likelihood of
having nephropathy, an amputation, foot ulcer, MI,
CABG, or angioplasty.
Table 4 presents the results of the multivariate regression
analysis for diabetes related prescription drug costs. An
examination of the regression reveals that demographic
characteristics, patient severity, complications, and type 2
diabetic classification as well as HbA1c classification all
helped to predict diabetes related prescription drug costs.
Specifically, individuals who were older, were diagnosed
with nephropathy, or were classified with type 2 diabetes
based upon a diagnosis of type 2 or diagnosis of type 2
and receipt of insulin had significantly lower diabetes-
related prescription drug costs. In contrast, individuals
who were commercially insured or self-insured, as well as
those with fair or poor HbA1c values had significantly
higher total diabetes-related prescription drug costs.
Table 4 also examines the factors which help to predict
total diabetes related medical costs. As with the regression
for diabetes related prescription drug costs, demographic
characteristics, patient severity, complications and comor-
bidities, type 2 diabetic classification, and HbA1c classifi-
cation all helped to predict costs. Compared to those
individuals who received oral antidiabetic agents without
a formal diagnoses of type 2 diabetes, individuals who
received a diagnoses with no receipt of antidiabetic agents
had significantly lower total diabetes related medical
costs. In contrast, individuals who received a diagnosis of
Table 3: Descriptive statistics – By HbA1c levels
Variable Good HbA1c (≤7) Fair HbA1c (>7 and ≤9) Poor HbA1c (>9)
Demographics
Mean Age, (SD) 65 (13) 61* (13) 54* ‡ (13)
Sex
% Female 47% 45% 47%
% Male 53% 55% 53%
Insurance
% Medicare 62% 47%* 30%* ‡
% Commercial 37% 52%* 70%* ‡
% Other 1% 1% <1%
Patient Severity
Mean # of All (diabetic+non-diabetic) Distinct Medications, 
(SD) prescribed in the pre-period
8.4 (5.5) 8.6 (5.5) 7.8* ‡ (5.6)
Mean total medical costs in 12 month pre-period (SD) 4,524 (8,660) 4,436 (10,774) 3,485* ‡ (7,658)
% Diagnosed with diabetes in the 12 month pre-period. 75% 87%* 88%*
Complications in Pre-Period
% Nephropathy 4.8% 4.4% 3.4%
% Neuropathy 4.1% 5.2%* 5.4%
% Retinopathy 2.6% 3.9%* 3.9%*
% Foot Ulcer 1.6% 1.8% 2.1%
% Amputation 0.2% 0.3% 0.3%
Comorbidities in Pre-Period
% Myocardial Infarction 2.8% 2.9% 2.8%
% Stroke 7.6% 5.1%* 4.5%*
% Coronary Artery Bypass Surgery 0.9% 1.0% 0.6%
% Angioplasty 1.6% 1.2% 1.2%
Mean Count of HbA1c Tests, (SD) 5.3 (2.8) 5.6* (2.8) 4.7* ‡ (2.7)
Sample Size 6,069 3,586 1,125
SD=Standard deviation.
*Significant below 0.05 compared to the good control group.
‡Significant below 0.05 between Fair and Poor control groups
Percentages are column percents.
Continuous variables analyzed using OLS regression, Poisson regression or Kruskal-Wallis.
Pairwise differences between groups using student's t-test, z-statistic or Mann-Whitney test.Cost Effectiveness and Resource Allocation 2006, 4:1 http://www.resource-allocation.com/content/4/1/1
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type 2 diabetes and received insulin had significantly
higher total diabetes related medical costs than individu-
als who received an oral antidiabetic agent only. Commer-
cial insurance, prior medical costs, comorbidities of
nephropathy, stroke or foot ulcer were all found to be sig-
nificant predictors of total diabetes related medical costs.
Finally, as with the diabetes related prescription drug
regression, individuals classified as having fair or poor
HbA1c  values had significantly higher diabetes related
total medical costs than individuals classified as having
good HbA1c values.
Table 5 examines the estimated costs derived from the
multivariate regressions. Specifically, Table 5 presents the
estimated mean per member per year costs associated
with a diagnosis of diabetes across different HbA1c ranges,
based upon model covariates held constant at their sam-
ple means. Results show that direct medical costs attribut-
able to type 2 diabetes are 16% lower for individuals with
good glycemic control than for those with fair ($1,505 vs.
$1,801, p < 0.05) control, and 20% lower for those with
good glycemic control than for those with poor ($1,505
vs. $1,871, p < 0.05) control. Prescription drug costs were
also significantly lower for individuals with good glyc-
emic control compared to those with fair ($377 vs. $465,
p < 0.05) or poor ($377 vs. $423, p < 0.05). There were no
differences between the fair and poor control groups.
Discussion
The findings from this study highlight the significant dif-
ferences in cost between three levels of glycemic control,
namely, good (HbA1c ≤7%), fair (HbA1c >7–9%), and
Table 4: Cost regressions
Variable Dependent Variable: 
Log of Diabetes-Related Prescription 
Drug Costs
Dependent Variable: 
Log of Diabetes-Related Total 
Medical Costs
Coefficient P Value Coefficient P Value
Patient Demographics
Age 0.994 <0.0001 1.004 0.063
FemaleA 0.978 0.321 0.964 0.329
Commercially InsuredB 1.742 <0.0001 1.180 0.002
Self-InsuredB 1.251 0.040 1.432 0.296
Patient Severity
Pre-Period Diabetes-Related Prescription Drug CostsC 1.001 <0.0001 --- ---
Pre-Period Diabetes-Related Total Medical CostsC --- --- 1.000 <0.0001
# of Distinct Antidiabetic Medications Used in Pre-Period 1.136 <0.0001 1.240 <0.0001
Comorbidities in the Pre-Period
Nephropathy 0.902 0.014 1.487 <0.0001
Stroke --- --- 1.317 <0.0001
Foot Ulcer --- --- 1.384 0.0002
Amputation --- --- 1.007 0.981
Retinopathy 1.025 0.520 --- ---
Complications in the Pre-Period
Angioplasty 0.902 0.214 --- ---
Myocardial Infarction 0.926 0.186 --- ---
Coronary Artery Bypass Surgery 0.839 0.055 0.695 0.097
Type 2 Diabetes Classification
Diagnosis of Type 2 DiabetesD 0.143 <0.0001 0.515 <0.0001
Diagnosis of Type 2 diabetes and Receipt of InsulinD 0.771 <0.0001 1.448 <0.0001
HbA1cClassification --- ---
FairE 1.231 <0.0001 1.196 <0.0001
PoorE 1.121 <0.0001 1.243 <0.0001
A – reference category male
B – reference category Medicare insurance
C – pre-period diabetes-related prescription drug costs used only in the diabetes-related prescription drug cost regression and pre-period total 
diabetes-related total medical costs used only in the total diabetes-related total medical costs regression.
D – reference category individuals who received an oral antidiabetic agent with no diagnosis of type 2 diabetes
E – reference category is classification of good glycemic control
Adjusted for age, gender, LOB (self-insured, commercial, other) prior (1 year) cost, count of distinct medications in the prior (1 year) period, 
diagnosis of diabetes in one prior (1 year period), type 2 diabetes classification (diagnosis of type 2, diagnosis of type 2 and receipt of insulin, or 
other), and HbA1c classification (fair, poor, or other). Diagnosis of procedure codes of nephropathy, retinopathy, angioplasty, CABG, stroke, MI, 
amputation, or foot ulcer in the year prior to index date were included in each of the specific models if had Wald p-values of <0.15 and they did not 
significantly change the Bayesian Information Criteria.Cost Effectiveness and Resource Allocation 2006, 4:1 http://www.resource-allocation.com/content/4/1/1
Page 7 of 8
(page number not for citation purposes)
poor (HbA1c  >9%). These results also offer valuable
insight into managed care healthcare resource use by level
of HbA1c control, specifically antidiabetes medications
usage.
Results indicate that level of glycemic control affects the
patient's treatment for diabetes when subjects were strati-
fied by use of antidiabetic medication and HbA1c level. For
example, individuals with good glycemic control were less
likely to treat their diabetes with medication and less
likely to be prescribed insulin (either alone or in conjunc-
tion with oral antidiabetic drugs). By contrast, individuals
with poor levels of glycemic control were significantly
more likely to treat their diabetes with insulin. This differ-
ence most likely exists because the patient in good control
is earlier in the course of the disease. [19,20]
Type 2 diabetes is a progressive disease that can initially be
effectively managed with diet and exercise in most cases.
[19] Eventually, pancreatic beta cell decline coupled with
increased insulin resistance eventually results in the need
for increased combinations of pharmacotherapy. [21]
Patients who are less controlled are more likely to have
exhausted available oral treatment options, as these
agents require viable insulin production from the pan-
creas in order to be maximally effective. [22] As beta cell
function from the pancreas declines, insulin production
will need to be supplemented artificially via insulin injec-
tion. [22]
Several studies of administrative claims data have demon-
strated an association between HbA1c levels and health-
care costs. After examining the relationship between
baseline HbA1c levels and cost, Gilmer et al. found a
$400–$4000 per patient cost savings over a 3 year period
for every 1% drop in HbA1c.[17] Wagner et al. had similar
results after comparing the costs of patients who
improved by at least 1% with patients whose HbA1c levels
did not improve or worsened. Their results indicate that
improvements in HbA1c levels among patients with diabe-
tes initially assessed as having poor HbA1c levels (>10%)
were associated with statistically significant lower
adjusted healthcare costs within 1 to 2 years of improve-
ment. [16] The results from the present study are in line
with this previous research. However, previous studies did
not categorize HbA1c levels for ease of interpretation by
ADA standards or HEDIS guidelines. In the current case,
the total diabetes attributable costs were significantly
higher for both the fair and poor HbA1c groups when com-
pared to patients with good HbA1c control (p < 0.05 for
both comparisons) (Table 3). Additionally, this trend was
evident when examining the prescription drug compo-
nent of diabetes attributable total costs.
These results point out that even patients considered to
have fair glycemic control by HEDIS guidelines, HbA1c of
>7–9%, have significantly higher total diabetes attributa-
ble costs as well as diabetes attributable prescription drug
costs, when compared to patients considered to be under
good glycemic control, < 7% HbA1c. Similarly, in a study
by Menzin et al., after controlling for age, sex, cancer,
duration of follow-up, and adjusting to 3 years, patients
with HbA1c levels <8% (good) had a statistically signifi-
cant reduced probability of inpatient admission com-
pared to those patients in either the 8–10% (fair) or >10%
(poor) HbA1c category, regardless of long-term diabetic
complication. These findings indicate that modest, incre-
mental improvements in HbA1c control (improving from
poor to fair) may not be adequate for attaining clinically
meaningful improvements and suggest that a goal of
improving to good HbA1c control could result in better
patient outcomes and even larger healthcare savings and
reduced healthcare resource utilization. It is important to
note that this study only examines costs directly attributa-
ble to diabetes (e.g. a diagnosis of type 2 diabetes or
receipt of an antidiabetic medication) and hence, does
not include the costs associated with diabetic complica-
tions such as neuropathy or retinopathy that is associated
with poor levels of glycemic control. As such, these results
may underestimate differences in diabetes related costs for
individuals with fair or poor levels of glycemic control.
Interpreting the findings of these analyses must be per-
formed in the context of the study design's limitations.
First, the analysis utilized data contained in one health
plan located in the Southeastern United States. While this
database was deemed to cover an adequately wide geo-
graphic distribution, the results may not be generalizable
Table 5: Estimated mean costs – Per member per year
Cost Good HbA1c (≤7) Fair HbA1c (>7 and ≤9) Poor HbA1c (>9)
Diabetic Prescription Drugs $377 ($366 – $390) $465* ($450 – $480) $423* ($400 – $449)
Total Diabetes Attributable Costs $1,505 ($1,441 – $1,571) $1,801* ($1,674 – $1,937) $1,871* ($1,684 – $2078)
Sample Size 6,069 3,586 1,125
*Significant below 0.05 compared to the good control group.
No differences between fair and poor control groups.
Confidence intervals given in parentheses.
Estimated costs from a generalized linear model with gamma as the family and logarithmic at the link and all covariates evaluated at the mean.Cost Effectiveness and Resource Allocation 2006, 4:1 http://www.resource-allocation.com/content/4/1/1
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to other populations. Second, while the database includes
pharmacological interventions that affect HbA1c levels,
this analysis was unable to capture patients' exposure to
diet and exercise, two interventions shown to have a pos-
itive impact on glycemic control. Third, the analysis was
unable to control for time from initial diagnosis, a factor
that may impact both levels of glycemic control and med-
ical costs. Fourth, the cost analysis was limited to those
costs attributable to a diagnosis of diabetes or receipt of an
antidiabetic agent. Because this analysis relied on diag-
nostic codes, the total costs and cost components may
therefore be underestimated. Lastly, the reliance on a
claims database means that individuals could not be
definitively classified as having type 2 diabetes. Specifi-
cally, this analysis chose to include individuals who
received oral antidiabetic agents independent of a formal
diagnosis of type 2 diabetes. However, it should be noted
that such a classification is common when conducting ret-
rospective database analyses. [23-25]
Conclusion
This study yields results supporting the use of glycemic
control as a surrogate measure for not only the risk of dia-
betic complications, but also diabetes attributable health-
care utilization and cost. Results indicate significant
differences in the use of diabetic medications between the
three levels of HbA1c control. In addition, the results indi-
cate that significantly lower diabetes attributable direct
medical costs and diabetic prescription drug costs are
associated with good HbA1c control than with fair or poor
HbA1c control. These results highlight the fact that there
are savings associated with aggressive improvement in
patients' glycemic control past the fair category considered
acceptable by HEDIS standards. It is anticipated that
improved pharmacological therapies will have a signifi-
cant impact on HbA1c levels, and consequently on health-
care costs.
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